Securities Code: 002038 Securities Abbreviation: Double-Crane Pharmaceutical Announcement No.: 2026-009
Beijing Double-Crane Pharmaceutical Co., Ltd. Announcement on the 2025 Profit Distribution Plan
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and that there are no false records, misleading statements, or major omissions.
I. Deliberation Procedures Beijing Double-Crane Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") held the Ninth Board of Directors' Ninth Meeting on April 27, 2026, which reviewed and approved the "Proposal on the 2025 Profit Distribution Plan." This profit distribution plan is subject to the approval of the Company's 2025 Shareholders' Meeting.
II. Basic情况 of the 2025 Profit Distribution Plan
- 2025 Profit Distributable Amount According to the audit by Dahua Certified Public Accountants (Special General Partnership), the Company's net profit attributable to the parent company in 2025 was -216,923,903.78 yuan. Adding the undistributed profit at the beginning of the year of 3,734,614,755.77 yuan, and deducting the ordinary share dividends paid in 2024 of 20,547,000 yuan and ordinary share dividends converted to share capital of 0.00 yuan, the actual profit distributable to shareholders is 3,497,143,851.99 yuan, without setting aside statutory reserves. The consolidated undistributed profit at the end of 2025 was 3,481,852,226.54 yuan. In accordance with the relevant rules of the Shenzhen Stock Exchange, based on the principle of the lower of the parent company's and the consolidated undistributed profit, the profit distributable to shareholders in 2025 is determined not to exceed 3,481,852,226.54 yuan.